Ipamorelin / Tesamorelin Blend Research Guide

Overview

What is the Ipamorelin / Tesamorelin Blend?

This blend pairs Ipamorelin, the most selective growth hormone secretagogue, with Tesamorelin (Egrifta), the only GHRH analog with FDA approval (indicated for reduction of excess abdominal fat in HIV-associated lipodystrophy). The combination targets GH release through two complementary receptor systems: Ipamorelin via the ghrelin/GHS receptor and Tesamorelin via the GHRH receptor on pituitary somatotrophs.

Tesamorelin is a 44-amino acid synthetic analog of human GHRH with a trans-3-hexenoic acid modification at the N-terminus that increases potency and resistance to enzymatic degradation. In clinical trials for lipodystrophy, Tesamorelin reduced trunk fat by an average of 17.5% over 26 weeks while preserving lean mass and without adversely affecting glucose metabolism. The compound stimulates pulsatile, physiological GH release rather than sustained supraphysiological levels.

The theoretical advantage of pairing Tesamorelin with Ipamorelin lies in the dual-receptor amplification of GH pulses. GHRH sets the amplitude of GH release while GHS receptor agonism increases pulse frequency. Together, the combination may achieve greater GH output per dose than either compound alone, similar to the CJC-1295/Ipamorelin combination but with the regulatory validation and extensive clinical data behind Tesamorelin's GHRH receptor activation.

Science

Mechanism of Action

The Ipamorelin/Tesamorelin blend achieves synergistic growth hormone release through the same dual-receptor paradigm as CJC-1295/Ipamorelin, but with a clinically validated GHRH component.

Tesamorelin: GHRH Receptor Agonism

Tesamorelin binds to the GHRH receptor on pituitary somatotrophs with high affinity. Its 44-amino acid sequence closely mirrors endogenous GHRH(1-44), but the trans-3-hexenoic acid modification at the N-terminus confers resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, extending its biological half-life. GHRH receptor activation triggers the adenylyl cyclase/cAMP/PKA signaling cascade, increasing both GH gene transcription and the amplitude of GH secretory bursts. Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — averaging 15–18% reduction at 26 weeks — mediated by GH-stimulated lipolysis [1].

Ipamorelin: GHS Receptor Agonism

Ipamorelin activates the GHS-R1a receptor, the same receptor that responds to endogenous ghrelin. This triggers phospholipase C/IP3-mediated calcium release from intracellular stores, increasing the frequency of GH pulses independently of the GHRH pathway. Ipamorelin is uniquely selective among GHRPs — at therapeutic doses, it does not significantly elevate cortisol, prolactin, or aldosterone, making it the cleanest available ghrelin receptor agonist [3].

Synergistic GH Amplification

When GHRH and GHS receptor signals arrive simultaneously at the somatotroph, the resulting GH output is multiplicative. Tesamorelin increases the size of each GH pulse while Ipamorelin increases the number of pulses, creating a physiological GH profile with significantly elevated total daily GH output. This dual-pathway stimulation has been shown to produce 3–5 fold greater GH release than either agent alone [4].

Visceral Fat Targeting

The Tesamorelin component provides a specific mechanism for visceral fat reduction that is well-characterized in clinical data. Growth hormone promotes lipolysis preferentially in visceral adipose tissue through upregulation of hormone-sensitive lipase (HSL) and downregulation of lipoprotein lipase (LPL) in visceral fat depots. This preferential visceral targeting is a distinguishing feature of Tesamorelin-mediated GH elevation compared to exogenous GH [2].

Dosing

Dosing Protocol

Dosing follows the same fasting-dependent principles as other GH secretagogue protocols. The pre-sleep dose is the most important timing window.

Protocol	Dose (each compound)	Frequency	Duration	Notes
Standard	100–200 mcg each	Once daily, pre-sleep	8–12 weeks	Fasted; most important timing window
Twice daily	100 mcg each	AM fasted + pre-sleep	8–12 weeks	Two GH pulses per day
Body composition	200 mcg each	Once daily, pre-sleep	12 weeks	Mirrors Tesamorelin clinical trial duration
Maintenance	100 mcg each	Once daily, pre-sleep	Ongoing	Long-term low-dose approach after initial cycle

Dosing Notes
Must inject fasted. Carbohydrates and fats blunt the GH response. Wait at least 2 hours after eating, and avoid food for 20–30 minutes post-injection.
The pre-sleep dose capitalizes on the natural nocturnal GH surge — this is the single most important timing.
Tesamorelin clinical data used a once-daily dosing paradigm, supporting the single injection approach.
Cycle 8–12 weeks on, 4 weeks off to prevent GHS receptor desensitization.
Body composition changes (particularly visceral fat reduction) typically become measurable at 8–12 weeks.

Preparation

Reconstitution Guide

Reconstitute the lyophilized Ipamorelin/Tesamorelin blend with bacteriostatic water. The peptides dissolve readily. Never shake the vial.

Remove the plastic cap from the blend vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
Draw 2 mL of bacteriostatic water into a sterile syringe. For a 5/5 mg (10 mg total) vial, this yields 2,500 mcg/mL of each peptide.
Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

5/5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg Ipamorelin + 2,500 mcg Tesamorelin per mL

100 mcg dose (of each) = 4 units (0.04 mL) on a 100-unit insulin syringe

200 mcg dose (of each) = 8 units (0.08 mL) on a 100-unit insulin syringe

Doses per vial: 50 doses at 100 mcg each, or 25 doses at 200 mcg each

Supplies Needed (12-Week Cycle at 200 mcg Once Daily)
4 vials Ipamorelin/Tesamorelin blend (5/5 mg each) — 100 doses at 200 mcg, covers 84 days with margin
2 vials bacteriostatic water (30 mL each)
85 insulin syringes (29–31 gauge, 100-unit)
Alcohol prep pads

Administration

Injection Technique

The Ipamorelin/Tesamorelin blend is administered via subcutaneous (SubQ) injection. Injection site does not affect efficacy — the peptides work systemically to stimulate pituitary GH release.

Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper arm.
Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Abdominal Injection for Body Composition Goals

While injection site does not affect the systemic GH response, Tesamorelin clinical trials used abdominal subcutaneous injection as the standard administration site. For researchers focused on body composition goals, abdominal injection sites are the conventional choice. Rotate between sites using a clock pattern around the navel, maintaining at least 1 inch between injection points. Allow at least 2 inches from the navel itself.

Storage

Storage & Stability

Proper storage is essential to maintain the biological activity of both peptide components.

Lyophilized (Powder)

2–8°C (36–46°F)

Refrigerator. Stable for 24+ months sealed.

Lyophilized (Long-term)

-20°C (-4°F)

Freezer. Extended stability beyond 2 years.

Reconstituted

2–8°C (36–46°F)

Refrigerate immediately. Use within 21 days.

Avoid

Do not freeze reconstituted solution

Protect from light. Heat accelerates degradation.

Storage Tips
Keep vials upright in the back of the refrigerator (most consistent temperature).
Tesamorelin is sensitive to temperature fluctuation — avoid placing vials in the refrigerator door.
Never re-freeze a reconstituted vial. Discard if left at room temperature for more than 2 hours.
Label reconstituted vials with the date to track the 21-day use window.

Safety

Side Effects & Considerations

The side effect profile benefits from extensive clinical data on Tesamorelin (from FDA approval trials) and Ipamorelin's documented selectivity. This combination may be the best-characterized GH secretagogue blend from a safety perspective.

Commonly Reported

Injection site reactions — erythema (redness), pruritus (itching), and mild swelling. Reported in Tesamorelin clinical trials as the most common adverse event.
Water retention — peripheral edema in the first 1–2 weeks, particularly in hands and feet. Usually self-resolving.
Arthralgia and myalgia — joint and muscle pain from elevated GH levels. More common at higher doses.
Tingling in extremities — a carpal tunnel-like sensation that may resolve with dose adjustment.
Transient head rush or flushing immediately after injection.

Tesamorelin-Specific Considerations

Tesamorelin may affect glucose metabolism. Clinical trials showed a small but statistically significant increase in fasting glucose in some subjects. Individuals with pre-diabetes or insulin resistance should monitor blood glucose closely.
In clinical trials, discontinuation of Tesamorelin resulted in a return of visceral fat toward baseline levels over 3–6 months, suggesting ongoing use may be needed to maintain body composition benefits.
Tesamorelin is contraindicated during pregnancy (Category X in FDA labeling for the approved indication).

Important

While Tesamorelin (Egrifta) has FDA approval for HIV-associated lipodystrophy, the Ipamorelin/Tesamorelin blend is classified as a research product and is not FDA-approved for any indication. All information presented here reflects published clinical and preclinical research and should not be construed as medical advice.

Protocols

Stacking Protocols

The Ipamorelin/Tesamorelin blend is primarily used for body composition goals and is occasionally combined with other compounds targeting complementary mechanisms.

Ipa/Tesa + BPC-157 (Body Recomp + Recovery)

For researchers combining body composition optimization with tissue repair, adding BPC-157 introduces localized healing capabilities. The elevated GH/IGF-1 from the blend may enhance BPC-157's tissue remodeling effects.

Peptide	Dose	Frequency	Duration
Ipa/Tesa Blend	200 mcg each	Once daily (pre-sleep)	8–12 weeks
BPC-157	250 mcg	Once daily	4–8 weeks

Lifestyle Optimization for Body Composition

Caloric management: The GH-mediated lipolysis from this blend is most effective in a slight caloric deficit or at maintenance. Excessive surplus will override fat loss mechanisms.
Resistance training: GH promotes lean mass preservation during caloric restriction. Combining the blend with progressive resistance training maximizes the body recomposition effect.
Sleep quality: The pre-sleep dose amplifies the natural nocturnal GH surge. Poor sleep quality significantly reduces the benefit. Prioritize 7–9 hours of uninterrupted sleep.
Fasting compliance: Strict. Eating within the fasting window before or after injection can reduce GH output by 50% or more.

Researchers studying the Ipamorelin/Tesamorelin blend often investigate these related compounds:

References

Literature & Citations

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed
Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. PubMed
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
Bowers CY. Synergistic release of growth hormone by GHRP and GHRH. J Pediatr Endocrinol. 1993;6(3-4):221-228. PubMed
Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, on body composition in HIV-associated lipodystrophy: a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PubMed
Veldhuis JD, Keenan DM, Bailey JN, et al. Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies. J Clin Endocrinol Metab. 2009;94(6):2137-2143. PubMed
Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PubMed

Ipamorelin / Tesamorelin Blend